The present study suggests that ABCB1 and hOCT1 transmembrane transporters have not a significant impact on the efficacy and tolerability of nilotinib when used as a first treatment for CML patients. This evidence concerns the gene SLC22A1 and chronic myelogenous leukemia, BCR-ABL1 positive.